AgeX Therapeutics’ CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Re...
July 09 2019 - 8:00AM
Business Wire
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a
biotechnology company focused on therapeutics for human aging,
announced today that founder and CEO Michael D. West, Ph.D. will
present at Ending Age-Related Diseases: Investment Prospects &
Advances in Research, from the Life Extension Advocacy Foundation
(LEAF), July 11-12 at The Cooper Union in New York City.
AgeX will participate in the following sessions on Thursday,
July 12:
- Presentation: As part of the session, “Creating
interventions against aging, Part 1” beginning at 9:40am EDT, Dr.
West will deliver a 20-minute presentation titled, “The Reversal of
the Aging of Human Cells: Strategies for Clinical
Implementation.”
- Panel: Dr. West will participate on a panel, “Unlocking
the Future Without Age-Related Diseases: Forecasts” at 3:50pm.
The full program may be found here. Event registration is
here.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform named induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s delivery
technology to stably engraft PureStem cell therapies and slowly
release iTR molecules in the body. AgeX is developing its core
product pipeline for use in the clinic to extend human healthspan,
and is seeking opportunities to form licensing and partnership
agreements around its broad IP estate and proprietary technology
platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in AgeX’s reports filed with the
Securities and Exchange Commissions (copies of which may be
obtained at www.sec.gov). Subsequent events and developments may
cause these forward-looking statements to change. AgeX specifically
disclaims any obligation or intention to update or revise these
forward-looking statements as a result of changed events or
circumstances that occur after the date of this release, except as
required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190709005317/en/
Media Contact for AgeX: Bill Douglass Gotham Communications, LLC
bill@gothamcomm.com (646) 504-0890
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Apr 2023 to Apr 2024